Compare Dyne Therapeutics Inc. Common Stock (DYN) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs United States Oil ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while United States Oil ETF trades at $153.3 (market cap $1.86B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and United States Oil ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and United States Oil ETF for 21 Days on average.
| DYN | USO | |
|---|---|---|
Market Cap | $2.81B | $1.86B |
Volume | 2,195,902 | 3,642,169 |
Sector | Health | — |
52-Week High | $26.78 | $161.86 |
52-Week Low | $14.60 | $66.17 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
USO trades at $153.09, up 1.36% with a bullish technical signal supported by moving averages. Recent Middle East tensions and OPEC+ production decisions create volatility in oil markets, though G-7 reserve releases aim to curb prices. The stock shows strong technical momentum with key resistance at $154.
Outlook remains volatile with geopolitical risks balanced against supply interventions. Investment opportunity exists for traders capitalizing on oil price swings, though regulatory and operational risks persist. The stock's performance remains tightly linked to crude oil price movements and global supply dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
